Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release

Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure. Read the Press Release

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release